What is Spritam
LevetiracetamThe Generic name of this drug
Treatment SummaryLevetiracetam is an anti-seizure medication used to treat epilepsy and other seizure disorders. It was approved for use in the US in 1999 and is different from other anti-epileptic drugs. Levetiracetam has a wide range of effectiveness and does not interact with other drugs, making it a preferred choice over other anti-epileptic drugs.
Kepprais the brand name
Spritam Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Keppra
Levetiracetam
2000
604
Approved as Treatment by the FDA
Levetiracetam, otherwise known as Keppra, is approved by the FDA for 1 uses like Seizures .Seizures
Effectiveness
How Spritam Affects PatientsLevetiracetam works to stop seizures, though it is not clear exactly how it does this. It is considered to be a relatively safe drug compared to other anti-epileptic medications. However, taking levetiracetam may increase the risk of suicidal thoughts or behaviours, so patients should be monitored for any signs of depression, suicidal thoughts, or odd behaviours.
How Spritam works in the bodyWe don't know exactly how levetiracetam works to treat epilepsy but it appears to bind to a protein called synaptic vesicle protein 2A (SV2A). This protein helps move neurotransmitters from inside the cell to outside the cell. Levetiracetam stimulates SV2A which may inhibit the release of neurotransmitters, but it only does this when there is a pathophysiological condition. It also affects GABAergic neurotransmission and calcium channels, though it is unclear how these actions help treat epilepsy.
When to interrupt dosage
The measure of Spritam is contingent upon the diagnosed affliction, including Seizures, Juvenile myoclonic epilepsy and Epilepsies. The dosage fluctuates depending on the method of delivery (e.g. Tablet, for suspension or Intravascular) featured in the table beneath.Condition
Dosage
Administration
Seizures
1000.0 mg, 10.0 mg/mL, 750.0 mg, 500.0 mg, , 100.0 mg/mL, 250.0 mg, 1500.0 mg, 5.0 mg/mL, 15.0 mg/mL, 500.0 mg/mL, 150.0 mg/mL
Tablet, for suspension, Intravascular, Injection, solution - Intravenous, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated, extended release - Oral, Tablet, Oral, , Injection, solution, concentrate, Solution - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, extended release - Oral, Intravenous, Tablet - Oral, Injection - Intravascular, Solution, Solution - Intravenous, Injection, Aerosol, Tablet, for suspension - Oral, Injection, solution, concentrate - Intravenous, Tablet, Chewable, Extended Release - Oral, Injection - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Chewable, Extended Release, Injection, solution, Aerosol - Oral, Injection, powder, lyophilized, for solution
Juvenile myoclonic epilepsy
1000.0 mg, 10.0 mg/mL, 750.0 mg, 500.0 mg, , 100.0 mg/mL, 250.0 mg, 1500.0 mg, 5.0 mg/mL, 15.0 mg/mL, 500.0 mg/mL, 150.0 mg/mL
Tablet, for suspension, Intravascular, Injection, solution - Intravenous, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated, extended release - Oral, Tablet, Oral, , Injection, solution, concentrate, Solution - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, extended release - Oral, Intravenous, Tablet - Oral, Injection - Intravascular, Solution, Solution - Intravenous, Injection, Aerosol, Tablet, for suspension - Oral, Injection, solution, concentrate - Intravenous, Tablet, Chewable, Extended Release - Oral, Injection - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Chewable, Extended Release, Injection, solution, Aerosol - Oral, Injection, powder, lyophilized, for solution
Epilepsies
1000.0 mg, 10.0 mg/mL, 750.0 mg, 500.0 mg, , 100.0 mg/mL, 250.0 mg, 1500.0 mg, 5.0 mg/mL, 15.0 mg/mL, 500.0 mg/mL, 150.0 mg/mL
Tablet, for suspension, Intravascular, Injection, solution - Intravenous, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated, extended release - Oral, Tablet, Oral, , Injection, solution, concentrate, Solution - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, extended release - Oral, Intravenous, Tablet - Oral, Injection - Intravascular, Solution, Solution - Intravenous, Injection, Aerosol, Tablet, for suspension - Oral, Injection, solution, concentrate - Intravenous, Tablet, Chewable, Extended Release - Oral, Injection - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Chewable, Extended Release, Injection, solution, Aerosol - Oral, Injection, powder, lyophilized, for solution
inadequate response to conventional therapy
1000.0 mg, 10.0 mg/mL, 750.0 mg, 500.0 mg, , 100.0 mg/mL, 250.0 mg, 1500.0 mg, 5.0 mg/mL, 15.0 mg/mL, 500.0 mg/mL, 150.0 mg/mL
Tablet, for suspension, Intravascular, Injection, solution - Intravenous, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated, extended release - Oral, Tablet, Oral, , Injection, solution, concentrate, Solution - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, extended release - Oral, Intravenous, Tablet - Oral, Injection - Intravascular, Solution, Solution - Intravenous, Injection, Aerosol, Tablet, for suspension - Oral, Injection, solution, concentrate - Intravenous, Tablet, Chewable, Extended Release - Oral, Injection - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Chewable, Extended Release, Injection, solution, Aerosol - Oral, Injection, powder, lyophilized, for solution
Idiopathic Generalized Epilepsy
1000.0 mg, 10.0 mg/mL, 750.0 mg, 500.0 mg, , 100.0 mg/mL, 250.0 mg, 1500.0 mg, 5.0 mg/mL, 15.0 mg/mL, 500.0 mg/mL, 150.0 mg/mL
Tablet, for suspension, Intravascular, Injection, solution - Intravenous, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated, extended release - Oral, Tablet, Oral, , Injection, solution, concentrate, Solution - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, extended release - Oral, Intravenous, Tablet - Oral, Injection - Intravascular, Solution, Solution - Intravenous, Injection, Aerosol, Tablet, for suspension - Oral, Injection, solution, concentrate - Intravenous, Tablet, Chewable, Extended Release - Oral, Injection - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Chewable, Extended Release, Injection, solution, Aerosol - Oral, Injection, powder, lyophilized, for solution
Tonic - clonic seizures
1000.0 mg, 10.0 mg/mL, 750.0 mg, 500.0 mg, , 100.0 mg/mL, 250.0 mg, 1500.0 mg, 5.0 mg/mL, 15.0 mg/mL, 500.0 mg/mL, 150.0 mg/mL
Tablet, for suspension, Intravascular, Injection, solution - Intravenous, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated, extended release - Oral, Tablet, Oral, , Injection, solution, concentrate, Solution - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, extended release - Oral, Intravenous, Tablet - Oral, Injection - Intravascular, Solution, Solution - Intravenous, Injection, Aerosol, Tablet, for suspension - Oral, Injection, solution, concentrate - Intravenous, Tablet, Chewable, Extended Release - Oral, Injection - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Chewable, Extended Release, Injection, solution, Aerosol - Oral, Injection, powder, lyophilized, for solution
myoclonic seizures
1000.0 mg, 10.0 mg/mL, 750.0 mg, 500.0 mg, , 100.0 mg/mL, 250.0 mg, 1500.0 mg, 5.0 mg/mL, 15.0 mg/mL, 500.0 mg/mL, 150.0 mg/mL
Tablet, for suspension, Intravascular, Injection, solution - Intravenous, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated, extended release - Oral, Tablet, Oral, , Injection, solution, concentrate, Solution - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, extended release - Oral, Intravenous, Tablet - Oral, Injection - Intravascular, Solution, Solution - Intravenous, Injection, Aerosol, Tablet, for suspension - Oral, Injection, solution, concentrate - Intravenous, Tablet, Chewable, Extended Release - Oral, Injection - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Chewable, Extended Release, Injection, solution, Aerosol - Oral, Injection, powder, lyophilized, for solution
Body weight >20kg
1000.0 mg, 10.0 mg/mL, 750.0 mg, 500.0 mg, , 100.0 mg/mL, 250.0 mg, 1500.0 mg, 5.0 mg/mL, 15.0 mg/mL, 500.0 mg/mL, 150.0 mg/mL
Tablet, for suspension, Intravascular, Injection, solution - Intravenous, Tablet, film coated, extended release, Tablet, film coated, Tablet, film coated, extended release - Oral, Tablet, Oral, , Injection, solution, concentrate, Solution - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, extended release - Oral, Intravenous, Tablet - Oral, Injection - Intravascular, Solution, Solution - Intravenous, Injection, Aerosol, Tablet, for suspension - Oral, Injection, solution, concentrate - Intravenous, Tablet, Chewable, Extended Release - Oral, Injection - Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Tablet, Chewable, Extended Release, Injection, solution, Aerosol - Oral, Injection, powder, lyophilized, for solution
Warnings
Spritam ContraindicationsCondition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Levetiracetam may interact with Toxoplasma Infections
Common Spritam Drug Interactions
Drug Name
Risk Level
Description
Azelastine
Major
Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Ethanol
Major
Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Oliceridine
Major
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Levetiracetam is combined with Oliceridine.
Sodium oxybate
Major
Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Thalidomide
Major
Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Spritam Toxicity & Overdose RiskThe lowest toxic dose of levetiracetam in humans is 10mg/kg. Signs of an overdose may include restlessness, aggression, sleepiness, decreased consciousness, shallow breathing, or a coma. There is no specific antidote for overdose, so treatments should focus on supporting the patient and managing their symptoms. Dialysis can be used to reduce the amount of drug in the bloodstream by up to 50% within 4 hours.
Spritam Novel Uses: Which Conditions Have a Clinical Trial Featuring Spritam?
At present, 3 active studies are assessing the potential of Spritam to reduce myoclonic seizures, Juvenile myoclonic epilepsy and Idiopathic Generalized Epilepsy.Condition
Clinical Trials
Trial Phases
myoclonic seizures
0 Actively Recruiting
Juvenile myoclonic epilepsy
0 Actively Recruiting
Idiopathic Generalized Epilepsy
1 Actively Recruiting
Phase 3
Seizures
4 Actively Recruiting
Phase 2, Phase 3
Body weight >20kg
0 Actively Recruiting
Tonic - clonic seizures
0 Actively Recruiting
Epilepsies
0 Actively Recruiting
inadequate response to conventional therapy
0 Actively Recruiting
Spritam Reviews: What are patients saying about Spritam?
3Patient Review
8/1/2017 My doctor has been steadily increasing my dosage every three months, as I'm still having seizures. They've become less frequent, but they're still occurring. Unfortunately, the medication also causes fatigue; however, this seems to be a common side effect of epilepsy medications.
Patient Q&A Section about spritam
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What is Spritam used for?
"Spritam is a medication used to treat seizures in both children and adults. It is effective against many types of seizures, including partial-onset, myoclonic, and tonic-clonic seizures. Spritam is available as a tablet that easily dissolves in your mouth."
Answered by AI
How does Xcopri work?
"This medication is used to treat partial onset seizure disorder. Its exact mechanism is unknown, but it might work by affecting some nerves that are linked to seizures."
Answered by AI
What should you not take with Keppra?
"Some common medications that may interact with Keppra are antidepressants, antiepileptics, and benzodiazepines."
Answered by AI
Who makes SPRITAM?
"You may report any side effects you experience to Aprecia Pharmaceuticals, LLC by calling 1-844-882-7732 or to the FDA by calling 1-800-FDA-1088. SPRITAM (levetiracetam) is an antiepileptic drug available as 250 mg, 500 mg, 750 mg, and 1000 mg round, white to off-white, spearmint-flavored tablets for oral suspension."
Answered by AI